Accessibility Statement Skip Navigation
  • Back to Global Sites
  • +972-77-2005042
  • Blog
  • Journalists
  • GDPR
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +972-77-2005042 from 8 AM - 11 PM IL

    • Contact
    • Contact

      +972-77-2005042
      from 8 AM - 11 PM IL

  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR

BELKIN Laser Completes Enrollment of its GLAUrious Pivotal Trial for Glaucoma Laser Treatment in Seconds


News provided by

BELKIN Laser

06 May, 2021, 19:26 IDT

Share this article

Share toX

Share this article

Share toX

YAVNE, Israel, May 6, 2021 /PRNewswire/ - BELKIN Laser, the Israel-based start-up bringing a fast, automated and non-invasive glaucoma laser treatment to market announced today that it has completed enrollment in its GLAUrious randomized controlled trial.

In this confirmatory, prospective, non-inferiority, observer masked RCT a total of 192 patients were randomized across two arms, SLT and DSLT. 6-month follow up for primary endpoint is expected in January of 2022 and 12-month follow up is expected in Q3 of 2022.

With 140 million people suffering from glaucoma and ocular hypertension worldwide, demand for a first-line drop less treatment for glaucoma far exceeds the ability to treat all patients effectively or at all. Current medical treatments for glaucoma come with low adherence, side effects and thus are less attractive to the patient. SLT laser treatments currently available on the market are time-intensive, involve contact with the eye and require specialized skills. BELKIN's innovation solves all of these issues with an automated, gentle treatment which can be completed in seconds, making it a unique treatment solution for both patients and doctors.

"Our disruptive innovation has the potential to significantly expand the treatment options available to glaucoma patients today by providing an intuitive and time efficient treatment which is unparalleled in its ease of use." stated Daria Lemann Blumenthal, CEO and Co-founder of BELKIN Laser. "Conclusion of enrollment is a significant milestone, and we are pleased to see our clinical activities proceed as planned."

About BELKIN Laser:

BELKIN Laser, an Israeli clinical-stage medical device company, established in 2013 and is developing an intuitive, automated, fast glaucoma laser treatment, aimed at promoting accessibility to first-line drop-less glaucoma care by allowing any ophthalmologist and other eye care providers to treat many more patients in any location. Visit the BELKIN Laser website to learn more.

Related Links:
www.belkin-laser.com
BELKIN Laser LinkedIn
BELKIN Laser YouTube

For Press Images, please visit our Dropbox

SOURCE BELKIN Laser

Modal title

Contact PR Newswire

  • +972-77-2005042
    from 8 AM - 11 PM IL

Global Sites

  • APAC
  • APAC - Traditional Chinese
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany

 

  • India
  • Indonesia
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland

 

  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921
Global Sites
  • Asia
  • Brazil
  • Canada
  • Csezh
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italie
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States
+972-77-2005042
from 8 AM - 11 PM IL
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • Cookie Settings
Copyright © 2026 Cision US Inc.